Company Profile

Forge Therapeutics Inc
Profile last edited on: 2/8/23      CAGE: 6XVV8      UEI: ZCWKWSWHAJD6

Business Identifier: Novel medicines: combining bio-inorganic with medicinal chemistry: ew class of antibiotics to fight gram-negative superbugs
Year Founded
2015
First Award
2016
Latest Award
2016
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3210 Merryfield Row
San Diego, CA 92121
   (619) 252-6995
   info@forgetherapeutics.com
   www.forgetherapeutics.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Potentially creating a new class of antibiotics, Forge Therapeutics finctioned as a biotechnology company developing novel medicines by combining bioinorganic with medicinal chemistry to target metalloenzymes. Metalloenzymes make up over 30% of all known enzymes in nature and are critically important for a wide range of biochemical processes and biological catalysis. Anchored in 15 years of work University of California San Diego (licensed by Forge) the firm has developed a fundamentally new approach for the discovery of metalloenzyme inhibitors by focusing first on the metal in the enzyme active site. The Cohen lab has pioneered the use of fragment based drug discovery (FBDD) to identify metalloenzyme inhibitors as well as forming significant insights into the understanding of bioinorganic chemistry for the benefit of human health. Forge’s lead program - LpxC, a zinc metalloenzyme - has been recognized as an attractive antibacterial target for more than 15 years as it is conserved across Gram-negative bacteria and not found in Gram-positive or human cells. However, lack of suitable chemical starting points has hampered development progress. In January 2023 it was announced that Blacksmith Medicines had acquired Forge Therapeutics:

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
20-24

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NIH $150,000
Project Title: Novel Small Molecule Inhibitors of Lpxc for Multi-Drug Resistant Gram-Negative Bacteria.

Key People / Management

  Zachary Zimmerman -- Founder and CEO

  Seth Cohen -- Founder

  David Puerta -- Founder,COO and VP of Discovery

  Min Teng -- Vice President of Chemistry

  Jamie Thorpe -- Office Lead

  Esther Van Den Boom -- CFO